Literature DB >> 2571429

Reperfusion injury and its pharmacologic modification.

L H Opie1.   

Abstract

Reperfusion injury includes a spectrum of events, such as reperfusion arrhythmias, vascular damage and no-reflow, and myocardial functional stunning. The concept of reperfusion injury remains controversial with many proposed mechanisms when applied to humans, whereas in animal models, there are two main proposed mechanisms: calcium over-load and formation of oxygen free radicals. To prove that reperfusion injury is specifically caused by reperfusion would require evidence that an intervention given at the time of reperfusion can diminish or abolish the injury as in the case of arrhythmias, which are thought to be mediated by excess recycling of cytosolic calcium with delayed afterdepolarizations and ventricular automaticity. In the case of myocardial stunning, the phenomenon may be mediated, at least in part, by a burst of free radicals formed within the first minute of reperfusion and improved by free radical scavengers given at the time of reperfusion. The alternate hypothesis is that cytosolic calcium overload damages mechanisms for normal intracellular calcium regulation so that the stunned myocardium responds to agents that are thought to increase intracellular cytosolic calcium, such as beta-receptor agonists. A further component of reperfusion injury, under active investigation, is microvascular damage with alterations at the level of platelets, leukocytes, and endothelial integrity. From the therapeutic point of view, the divergent results of experimental interventions and the possibility that the abrupt onset of reperfusion in animals differs from the situation in humans with thrombolysis means that the best way currently available to limit reperfusion injury is by minimizing the ischemic period by early reperfusion and by optimizing the metabolic status of the ischemic myocardium at the end of the ischemic period.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571429     DOI: 10.1161/01.cir.80.4.1049

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  89 in total

Review 1.  Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality?

Authors:  D M Yellon; G F Baxter
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

2.  Reperfusion Injury: Does It Exist and Does It Have Clinical Relevance?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

3.  Reperfusion Phenomena Suggestive of Reperfusion Injury in Patients with Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

4.  Does Reperfusion Injury Exist?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

5.  Lethal Myocardial Reperfusion Injury: Does it Exist, Should We Treat It?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

6.  Cardioprotective effects of N-hydroxyguanidine PR5 in myocardial ischaemia and reperfusion in rats.

Authors:  M Veveris; M Dambrova; H Cirule; D Meirena; I Kalvinsh; J E Wikberg
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

Review 7.  Treating myocardial infarction in the post-GUSTO era. A European perspective.

Authors:  M J de Boer; F Zijlstra
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

8.  Vitamins Q and E, extracorporal circulation and hemolysis.

Authors:  J Karlsson; R Ronneberg; B Semb
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

9.  Low molecular weight iron and the oxygen paradox in isolated rat hearts.

Authors:  A Voogd; W Sluiter; H G van Eijk; J F Koster
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

10.  Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats.

Authors:  G Wölkart; X Pang; H Stessel; M Kirchengast; F Brunner
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.